Show simple item record

dc.contributor.authorCorrie, P
dc.contributor.authorMatin, R
dc.contributor.authorGupta, Avinash
dc.contributor.authorQian, W
dc.contributor.authorWordsworth, S
dc.contributor.authorGibbons, E
dc.contributor.authorChhabra, A
dc.contributor.authorHarman, C
dc.contributor.authorMather, C
dc.contributor.authorMiddleton, M
dc.date.accessioned2019-04-29T09:49:02Z
dc.date.available2019-04-29T09:49:02Z
dc.date.issued2018en
dc.identifier.citationCorrie PG, Matin RN, Gupta A, Qian W, Wordsworth S, Gibbons E, et al. 1300TiP A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM). Ann Oncol. 2018;29(suppl_8):464.en
dc.identifier.doi10.1093/annonc/mdy289.056en
dc.identifier.urihttp://hdl.handle.net/10541/621808
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy289.056en
dc.titleA randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentOncology Centre, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-04-20T11:18:01Z


Files in this item

Thumbnail
Name:
561660.pdf
Size:
90.60Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record